{"url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485283/", "query": "oral chelation heart disease", "contents": "<?xml version=\"1.0\" encoding=\"utf-8\"?>\n<!DOCTYPE html PUBLIC \"-//W3C//DTD XHTML 1.0 Transitional//EN\" \"http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd\">\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\">\n    \n    <head><meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n        <!-- AppResources meta begin -->\n        <script type=\"text/javascript\">var ncbi_startTime = new Date();</script>\n        <!-- AppResources meta end -->\n        \n        <!-- TemplateResources meta begin -->\n        <meta name=\"paf_template\" content=\"\" />\n\n        <!-- TemplateResources meta end -->\n        \n        <!-- Logger begin -->\n        <meta name=\"ncbi_db\" content=\"pmc\" /><meta name=\"ncbi_pdid\" content=\"article\" /><meta name=\"ncbi_acc\" content=\"\" /><meta name=\"ncbi_domain\" content=\"pakjmedsci\" /><meta name=\"ncbi_report\" content=\"record\" /><meta name=\"ncbi_type\" content=\"fulltext\" /><meta name=\"ncbi_objectid\" content=\"\" /><meta name=\"ncbi_pcid\" content=\"/articles/PMC4485283/\" /><meta name=\"ncbi_app\" content=\"pmc\" />\n        <!-- Logger end -->\n        \n        <title>Efficacy and adverse effects of oral chelating therapy (deferasirox) in multi-transfused Pakistani children with \u03b2-thalassemia major</title>\n        \n        <!-- AppResources external_resources begin -->\n        <link rel=\"stylesheet\" href=\"/core/jig/1.14.8/css/jig.min.css\" /><script type=\"text/javascript\" src=\"/core/jig/1.14.8/js/jig.min.js\"></script>\n\n        <!-- AppResources external_resources end -->\n        \n        <!-- Page meta begin -->\n        <meta name=\"robots\" content=\"INDEX,NOFOLLOW,NOARCHIVE\" /><link rel=\"canonical\" href=\"/pmc/articles/PMC4485283/\" /><link rel=\"schema.DC\" href=\"http://purl.org/DC/elements/1.0/\" /><meta name=\"citation_journal_title\" content=\"Pakistan Journal of Medical Sciences\" /><meta name=\"citation_title\" content=\"Efficacy and adverse effects of oral chelating therapy (deferasirox) in multi-transfused Pakistani children with \u03b2-thalassemia major\" /><meta name=\"citation_authors\" content=\"Muzamil Shabana Ejaz, Shagufta Baloch, Fehmina Arif\" /><meta name=\"citation_date\" content=\"May-Jun 2015\" /><meta name=\"citation_issue\" content=\"3\" /><meta name=\"citation_volume\" content=\"31\" /><meta name=\"citation_firstpage\" content=\"621\" /><meta name=\"citation_doi\" content=\"10.12669/pjms.313.6972\" /><meta name=\"citation_abstract_html_url\" content=\"/pmc/articles/PMC4485283/?report=abstract\" /><meta name=\"citation_pmid\" content=\"26150856\" /><meta name=\"DC.Title\" content=\"Efficacy and adverse effects of oral chelating therapy (deferasirox) in multi-transfused Pakistani children with \u03b2-thalassemia major\" /><meta name=\"DC.Type\" content=\"Text\" /><meta name=\"DC.Publisher\" content=\"Professional Medical Publications\" /><meta name=\"DC.Contributor\" content=\"Muzamil Shabana Ejaz\" /><meta name=\"DC.Contributor\" content=\"Shagufta Baloch\" /><meta name=\"DC.Contributor\" content=\"Fehmina Arif\" /><meta name=\"DC.Date\" content=\"May-Jun 2015\" /><meta name=\"DC.Identifier\" content=\"10.12669/pjms.313.6972\" /><meta name=\"DC.Language\" content=\"en\" /><meta property=\"og:title\" content=\"Efficacy and adverse effects of oral chelating therapy (deferasirox) in multi-transfused Pakistani children with \u03b2-thalassemia major\" /><meta property=\"og:type\" content=\"article\" /><meta property=\"og:description\" content=\"To determine the efficacy and adverse effects of oral chelation therapy (deferasirox) in multi-transfused \u03b2-thalassemia major patients visiting pediatric thalassemia clinic in Civil Hospital Karachi.This prospective study was conducted at pediatric ...\" /><meta property=\"og:url\" content=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485283/\" /><meta property=\"og:site_name\" content=\"PubMed Central (PMC)\" /><meta property=\"og:image\" content=\"https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png\" /><meta name=\"twitter:card\" content=\"summary\" /><meta name=\"twitter:site\" content=\"@ncbi\" /><link rel=\"stylesheet\" href=\"/corehtml/pmc/css/3.6/pmc.min.css\" type=\"text/css\" /><link rel=\"stylesheet\" href=\"/corehtml/pmc/css/3.6/pmc_extras_prnt.min.css\" type=\"text/css\" media=\"print\" /><script type=\"text/javascript\" src=\"/corehtml/pmc/js/common.min.js\">//</script><script type=\"text/javascript\" src=\"/corehtml/pmc/js/NcbiTagServer.min.js\">//</script><meta name=\"citationexporter\" content=\"backend:'/pmc/utils/ctxp/'\" /><script type=\"text/javascript\" src=\"/corehtml/pmc/ctxp/jquery.citationexporter.js\">//</script><link rel=\"stylesheet\" href=\"/corehtml/pmc/ctxp/citationexporter.css\" type=\"text/css\" /><script type=\"text/javascript\" src=\"/core/mathjax/2.6.1/MathJax.js?config=/corehtml/pmc/js/mathjax-config-classic.3.4.js\"></script><script type=\"text/javascript\" src=\"/corehtml/pmc/js/large-obj-scrollbars.min.js\"></script><script type=\"text/javascript\">window.name=\"mainwindow\";</script><style type=\"text/css\">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-pakjmedsci.gif);background-size: auto, contain}</style><style type=\"text/css\">.print-view{display:block}</style><style type=\"text/css\">\n        div.pmc_para_cit li.highlight,\n        div.pmc_para_cit li.highlight .one_line_source\n        { background: #E0E0E0; }\n        a.bibr.highlight { background: #E0E0E0; } \n      </style><meta name=\"cited_in_systematic_reviews\" content=\"\" /><link rel=\"alternate\" type=\"application/epub+zip\" href=\"/pmc/articles/PMC4485283/epub/\" /><link rel=\"alternate\" type=\"application/pdf\" href=\"/pmc/articles/PMC4485283/pdf/PJMS-31-621.pdf\" />\n\n        <!-- Page meta end -->\n    <link rel=\"shortcut icon\" href=\"//www.ncbi.nlm.nih.gov/favicon.ico\" /><meta name=\"ncbi_phid\" content=\"F4FC524A81E984410000000000770068\" /><link type=\"text/css\" rel=\"stylesheet\" href=\"//static.pubmed.gov/portal/portal3rc.fcgi/4132802/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4048120/3846471/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4120508/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4052581/9685/3549676/3609192/3609193/3609213/3395586/3855312.css\" /><link type=\"text/css\" rel=\"stylesheet\" href=\"//static.pubmed.gov/portal/portal3rc.fcgi/4132802/css/3411343/3882866/3929378.css\" media=\"print\" /></head>\n    <body class=\"article\">\n        <div class=\"grid\">\n            <div class=\"col twelve_col nomargin shadow\">\n                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->\n                <div class=\"sysmessages\">\n                    <noscript>\n\t<p class=\"nojs\">\n\t<strong>Warning:</strong>\n\tThe NCBI web site requires JavaScript to function. \n\t<a href=\"/guide/browsers/#enablejs\" title=\"Learn how to enable JavaScript\" target=\"_blank\">more...</a>\n\t</p>\n\t</noscript>\n                </div>\n                <!--/.sysmessage-->\n                <div class=\"wrap\">\n                    <div class=\"page\">\n                        <div class=\"top\">\n                            <div class=\"universal_header\" id=\"universal_header\"><ul class=\"inline_list jig-ncbimenu ui-ncbimenu resources_list\" id=\"navcontent\"><li class=\"ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt\"><a class=\"ui-ncbimenu-link-first\" href=\"/\" role=\"banner\" title=\"NCBI Home\" id=\"ncbihome\" accesskey=\"1\"><span class=\"offscreen_noflow\">NCBI</span><img src=\"//static.pubmed.gov/portal/portal3rc.fcgi/4132802/img/28977\" class=\"ncbi_logo\" title=\"NCBI\" alt=\"NCBI Logo\" /></a></li><li class=\"offscreen_noflow ui-ncbimenu-item-skip access\"><a href=\"#maincontent\" title=\"Skip to the content\" tabindex=\"0\" accesskey=\"3\">Skip to main\n                        content</a></li><li class=\"offscreen_noflow ui-ncbimenu-item-skip access\"><a href=\"#navcontent\" title=\"Skip to the navigation\" tabindex=\"0\" accesskey=\"4\">Skip to\n                        navigation</a></li><li id=\"resource-menu\" class=\"topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset\"><a class=\"ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown\" href=\"/static/header_footer_ajax/submenu/#resources\">Resources</a></li><li id=\"all-howtos-menu\" class=\"topmenu ui-helper-reset ui-ncbimenu-item-first\"><a class=\"ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown\" href=\"/static/header_footer_ajax/submenu/#howto\">How To</a></li><li class=\"offscreen_noflow ui-ncbimenu-item-skip access\"><a href=\"/guide/browsers/#accesskeys\" title=\"About My NCBI Accesskeys\" tabindex=\"0\" accesskey=\"0\">About NCBI Accesskeys</a></li></ul><div class=\"myncbi\"><span id=\"myncbiusername\" style=\"display:none\"><a href=\"/account/settings/\" id=\"mnu\" title=\"Edit account settings\"></a></span><a accesskey=\"2\" href=\"/myncbi/\" id=\"myncbi\" style=\"display:none\">My NCBI</a><a href=\"/account/\" id=\"sign_in\">Sign in to NCBI</a><a href=\"/account/signout/\" id=\"sign_out\" style=\"display:none\">Sign Out</a></div></div>\n                            <div class=\"header\">\n    <div class=\"res_logo\">\n  <h1 class=\"img_logo\"><a href=\"/pmc/\" class=\"pmc_logo offscreen\">PMC</a></h1>\n  <div class=\"NLMLogo\">\n    <a href=\"https://www.nlm.nih.gov/\" title=\"US National Library of Medicine\">US National Library of Medicine</a>\n    <br />\n    <a href=\"https://www.nih.gov/\" title=\"National Institutes of Health\">National Institutes of Health</a>\n  </div>\n</div>\n    <div class=\"search\"><form method=\"get\" action=\"/pmc/\"><div class=\"search_form\"><label for=\"database\" class=\"offscreen_noflow\">Search database</label><select id=\"database\"><optgroup label=\"Recent\"><option value=\"pmc\" selected=\"selected\" class=\"last\" data-ac_dict=\"pmc-search-autocomplete\">PMC</option></optgroup><optgroup label=\"All\"><option value=\"gquery\">All Databases</option><option value=\"assembly\">Assembly</option><option value=\"bioproject\">BioProject</option><option value=\"biosample\">BioSample</option><option value=\"biosystems\">BioSystems</option><option value=\"books\">Books</option><option value=\"clinvar\">ClinVar</option><option value=\"clone\">Clone</option><option value=\"cdd\">Conserved Domains</option><option value=\"gap\">dbGaP</option><option value=\"dbvar\">dbVar</option><option value=\"nucest\">EST</option><option value=\"gene\">Gene</option><option value=\"genome\">Genome</option><option value=\"gds\">GEO DataSets</option><option value=\"geoprofiles\">GEO Profiles</option><option value=\"nucgss\">GSS</option><option value=\"gtr\">GTR</option><option value=\"homologene\">HomoloGene</option><option value=\"medgen\">MedGen</option><option value=\"mesh\">MeSH</option><option value=\"ncbisearch\">NCBI Web Site</option><option value=\"nlmcatalog\">NLM Catalog</option><option value=\"nuccore\">Nucleotide</option><option value=\"omim\">OMIM</option><option value=\"pmc\" data-ac_dict=\"pmc-search-autocomplete\">PMC</option><option value=\"popset\">PopSet</option><option value=\"probe\">Probe</option><option value=\"protein\">Protein</option><option value=\"proteinclusters\">Protein Clusters</option><option value=\"pcassay\">PubChem BioAssay</option><option value=\"pccompound\">PubChem Compound</option><option value=\"pcsubstance\">PubChem Substance</option><option value=\"pubmed\">PubMed</option><option value=\"pubmedhealth\">PubMed Health</option><option value=\"snp\">SNP</option><option value=\"sparcle\">Sparcle</option><option value=\"sra\">SRA</option><option value=\"structure\">Structure</option><option value=\"taxonomy\">Taxonomy</option><option value=\"toolkit\">ToolKit</option><option value=\"toolkitall\">ToolKitAll</option><option value=\"toolkitbook\">ToolKitBook</option><option value=\"toolkitbookgh\">ToolKitBookgh</option><option value=\"unigene\">UniGene</option></optgroup></select><div class=\"nowrap\"><label for=\"term\" class=\"offscreen_noflow\" accesskey=\"/\">Search term</label><div class=\"nowrap\"><input type=\"text\" name=\"term\" id=\"term\" title=\"Search PMC. Use up and down arrows to choose an item from the autocomplete.\" value=\"\" class=\"jig-ncbiclearbutton jig-ncbiautocomplete\" data-jigconfig=\"dictionary:'pmc-search-autocomplete',disableUrl:'NcbiSearchBarAutoComplCtrl'\" autocomplete=\"off\" data-sbconfig=\"ds:'no',pjs:'no',afs:'yes'\" /></div><button id=\"search\" type=\"submit\" class=\"button_search nowrap\" cmd=\"go\">Search</button></div></div></form><ul class=\"searchlinks inline_list\"><li>\n                        <a href=\"/pmc/advanced/\">Advanced</a>\n                    </li><li>\n                        <a href=\"/pmc/journals/\">Journal list</a>\n                    </li><li class=\"help\">\n                        <a target=\"_blank\" href=\"/books/NBK3825/\">Help</a>\n                    </li></ul></div>\n</div>\n\n                            \n                            \n                        <!--<component id=\"Page\" label=\"headcontent\"/>-->\n                            \n                        </div>\n                        <div class=\"content\">\n                            <!-- site messages -->\n                            <div class=\"container\">\n    <div id=\"maincontent\" class=\"content eight_col col\">\n        <div class=\"navlink-box\">\n            <ul class=\"page-breadcrumbs inline_list small\"><li class=\"journal-list\"><a href=\"/pmc/journals/\" class=\"navlink\">Journal List</a></li><li class=\"archive\"><a class=\"navlink\" href=\"/pmc/journals/2162/\">Pak J Med Sci</a></li><li class=\"issue-page\"><a class=\"navlink\" href=\"/pmc/issues/254739/\">v.31(3); May-Jun 2015</a></li><li class=\"accid\">PMC4485283</li></ul>\n        </div>\n\n        <!-- Journal banner -->\n        <div class=\"pmc-page-banner whole_rhythm\"><div><img src=\"/corehtml/pmc/pmcgifs/logo-pakjmedsci.gif\" alt=\"Logo of pakjmedsci\" usemap=\"#logo-imagemap\" /><map id=\"logo-imagemap\" name=\"logo-imagemap\"><area alt=\"Link to Publisher's site\" title=\"Link to Publisher's site\" shape=\"default\" coords=\"0,0,499,74\" href=\"http://pjms.com.pk/\" target=\"pmc_ext\" ref=\"reftype=publisher&amp;article-id=4485283&amp;issue-id=254739&amp;journal-id=2162&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal\" /></map></div> </div>\n        \n        <!--component id='MainPortlet' label='search-reference'/-->\n        \n        <!-- Book content -->\n        <div class=\"\">\n            \n        \n            \n            <div class=\"hide-overflow article lit-style content pmc-wm slang-all page-box\"><!--main-content--><div class=\"jig-ncbiinpagenav\" data-jigconfig=\"smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden'\"><div class=\"fm-sec half_rhythm no_top_margin\"><div class=\"fm-citation half_rhythm no_top_margin clearfix\"><div class=\"small\"><div class=\"inline_block eight_col va_top\"><div><div><span class=\"cit\"><span id=\"pmcmata\">Pak J Med Sci</span>. 2015 May-Jun; 31(3): 621\u2013625. </span></div><div>  <span class=\"doi\">doi:\u00a0 <a href=\"//dx.doi.org/10.12669%2Fpjms.313.6972\" target=\"pmc_ext\" ref=\"reftype=other&amp;article-id=4485283&amp;issue-id=254739&amp;journal-id=2162&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI&amp;rendering-type=normal\">10.12669/pjms.313.6972</a></span></div></div></div><div class=\"inline_block four_col va_top show-overflow align_right\"><div class=\"fm-citation-ids\"><div class=\"fm-citation-pmcid\"><span class=\"fm-citation-ids-label\">PMCID: </span><span>PMC4485283</span></div></div></div></div></div><h1 class=\"content-title\">Efficacy and adverse effects of oral chelating therapy (deferasirox) in multi-transfused Pakistani children with &#x003b2;-thalassemia major</h1><div class=\"half_rhythm\"><div class=\"contrib-group fm-author\"><a href=\"/pubmed/?term=Ejaz%20MS%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=26150856\">Muzamil Shabana Ejaz</a>,<sup>1</sup><sup></sup> <a href=\"/pubmed/?term=Baloch%20S%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=26150856\">Shagufta Baloch</a>,<sup>2</sup> and  <a href=\"/pubmed/?term=Arif%20F%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=26150856\">Fehmina Arif</a><sup>3</sup></div></div><div class=\"fm-panel small half_rhythm\"><div class=\"fm-authors-info fm-panel hide half_rhythm\" id=\"id1779144_ai\" style=\"display:none\"><div class=\"fm-affl\" lang=\"en\"><sup>1</sup>Dr. Muzamil Shabana Ejaz, Associate Professor, Department of Pediatrics Dow University of Health Sciences Civil Hospital Karachi, Karachi - Pakistan</div><div class=\"fm-affl\" lang=\"en\"><sup>2</sup>Dr. Shagufta Baloch, FCPS Trainee, Department of Pediatrics Dow University of Health Sciences Civil Hospital Karachi, Karachi - Pakistan</div><div class=\"fm-affl\" lang=\"en\"><sup>3</sup>Prof. Fehmina Arif, Professor, Department of Pediatrics Dow University of Health Sciences Civil Hospital Karachi, Karachi - Pakistan</div><div id=\"cor1\"> Correspondence: Dr. Muzamil Shabana Ejaz, Associate Professor, Department of Paediatrics, Dow University of Health Sciences Civil Hospital Karachi, Karachi - Pakistan. E-mail: <a href=\"mailto:dev@null\" data-email=\"moc.oohay@80zajelimazum\" class=\"oemail\">moc.oohay@80zajelimazum</a></div></div><div class=\"togglers\"><a href=\"#\" class=\"pmctoggle\" rid=\"id1779144_ai\">Author information <span>\u25ba</span></a> <a href=\"#\" class=\"pmctoggle\" rid=\"id1779144_an\">Article notes <span>\u25ba</span></a> <a href=\"#\" class=\"pmctoggle\" rid=\"id1779144_cpl\">Copyright and License information <span>\u25ba</span></a></div><div class=\"fm-article-notes fm-panel hide half_rhythm\" id=\"id1779144_an\" style=\"display:none\"><div class=\"fm-pubdate half_rhythm\">Received 2014 Nov 27; Revised 2015 Apr 16; Accepted 2015 Mar 12.</div></div><div class=\"fm-cpl-info fm-panel hide half_rhythm\" id=\"id1779144_cpl\" style=\"display:none\"><div class=\"fm-copyright half_rhythm\"><a href=\"/pmc/about/copyright/\">Copyright</a> : &#x000a9; Pakistan Journal of Medical Sciences</div><div class=\"fm-copyright half_rhythm\">This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<a href=\"http://creativecommons.org/licenses/by/3.0\" ref=\"reftype=extlink&amp;article-id=4485283&amp;issue-id=254739&amp;journal-id=2162&amp;FROM=Article%7CFront%20Matter&amp;TO=External%7CLink%7CURI&amp;rendering-type=normal\" target=\"pmc_ext\">http://creativecommons.org/licenses/by/3.0</a>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</div></div></div><div id=\"pmclinksbox\" class=\"links-box fm-panel whole_rhythm hidden\"></div></div><div class=\"sec\"></div><div id=\"__abstractid1075657\" lang=\"en\" class=\"tsec sec\"><h2 class=\"head no_bottom_margin\" id=\"__abstractid1075657title\">Abstract</h2><!--article-meta--><div><div id=\"st1\" class=\"sec sec-first\"><h3>Objective:</h3><p id=\"__p1\" class=\"p p-first-last\">To determine the efficacy and adverse effects of oral chelation therapy (deferasirox) in multi-transfused &#x003b2;-thalassemia major patients visiting pediatric thalassemia clinic in Civil Hospital Karachi.</p></div><div id=\"st2\" class=\"sec\"><h3>Methods:</h3><p id=\"__p2\" class=\"p p-first-last\">This prospective study was conducted at pediatric thalassemia clinic of Civil Hospital Karachi. Hundred multi-transfused &#x003b2;-thalassemia patients registered in the clinic for oral iron chelation therapy were included in the study. Information regarding clinical and laboratory parameters including abdominal pain, jaundice, serum ferritin, creatinine and serum transaminase levels were recorded on a Performa and data was analyzed through SPSS 16.</p></div><div id=\"st3\" class=\"sec\"><h3>Results:</h3><p id=\"__p3\" class=\"p p-first-last\">Hundred patients were stratified into two age groups, 54% were below and 46% were above nine year. Majority were males, 62% and 38% were females. Abdominal pain 41%, nausea 31%, vomiting 15%, jaundice 15% and elevated serum creatinine 11.5% were frequently observed clinical adverse effects in this study. Serum glutamic pyruvic transaminase (SGPT) level was statistically significant compared with initial visit and six months after optimal chelation therapy (p=0.030). Although Serum ferritin was decreased but it was not statistically significant (p=0.929).</p></div><div id=\"st4\" class=\"sec sec-last\"><h3>Conclusion:</h3><p id=\"__p4\" class=\"p p-first-last\">Deferasirox is an effective oral chelation agent for &#x003b2;-thalassemia major patients. Most common adverse effects of the drug are abdominal pain, nausea, vomiting, and elevation of liver enzymes.</p></div></div><div class=\"sec\"><strong class=\"kwd-title\">KEY WORDS: </strong><span class=\"kwd-text\">Adverse effects, Children, Deferasirox, Efficacy, Oralchelation, Thalassemia</span></div></div><div id=\"sec1-1\" class=\"tsec sec\"><h2 class=\"head no_bottom_margin\" id=\"sec1-1title\">INTRODUCTION</h2><p id=\"__p5\" class=\"p p-first\">&#x003b2;-thalassemia is one of the major health problems in Pakistan with a carrier rate of 5-8%.<a href=\"#ref1\" rid=\"ref1\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_511871658\">1</a> Thalassemia major patients require regular blood transfusions which in turn lead to secondary iron overload.<a href=\"#ref2\" rid=\"ref2\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_511871655\">2</a> They need lifelong chelation therapy to prevent complications associated with chronic iron over load including liver and cardiac diseases, retardation of growth and sexual development during adolescence.<a href=\"#ref3\" rid=\"ref3\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_511871661\">3</a>,<a href=\"#ref4\" rid=\"ref4\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_511871639\">4</a></p><p id=\"__p6\">Multiple iron chelating drugs with various regimens and mode of administration are used in transfusion dependent &#x003b2;-thalassemia major patients including parenteral deferoxamine, oral deferiprone and deferasirox. These chelating agents showed variable efficacy and side effects.<a href=\"#ref5\" rid=\"ref5\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_511871642\">5</a> Initial chelation therapy with deferoxamine was associated with poor compliance due to slow parenteral infusions and poor long-term outcome therefore oral chelating drugs deferasirox and deferiprone were introduced to prevent complications of iron over load, which showed improved compliance and efficacy.<a href=\"#ref6\" rid=\"ref6\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_511871652\">6</a> However side effects including arthritis, 5-20%, neutropenia, 5%, and severe agranulocytosis, 0.5%, were observed in patients treated with deferiprone which limited its use.<a href=\"#ref7\" rid=\"ref7\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_511871656\">7</a> Deferasirox provides an effective alternative to deferiprone and deferoxamine in multi-transfused patients especially with intolerance and poor compliance to these drugs.<a href=\"#ref8\" rid=\"ref8\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_511871638\">8</a> It is recommended as once daily dose in children more than two year of age.<a href=\"#ref9\" rid=\"ref9\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_511871648\">9</a>,<a href=\"#ref10\" rid=\"ref10\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_511871654\">10</a> Deferasirox have high iron binding capacity and selectivity.<a href=\"#ref11\" rid=\"ref11\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_511871644\">11</a> It can reduce serum ferritin levels in dose dependent manner and is relatively a safe drug but treatment requires individualization with careful dose adjustment and proper monitoring.<a href=\"#ref9\" rid=\"ref9\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_511871665\">9</a>,<a href=\"#ref10\" rid=\"ref10\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_511871647\">10</a> Apart from reduction in major parameters including serum ferritin, liver iron concentration and toxic labile plasma iron, deferasirox has also reported to decrease and prevent cardiac iron overload with continuous long term therapy.<a href=\"#ref12\" rid=\"ref12\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_511871636\">12</a></p><p id=\"__p7\">Studies have shown that deferasirox stabilizes serum ferritin and liver iron concentrations when used in a dose of 20mg/kg/day whereas it significantly reduces these indicators and leads to negative iron balance in transfusion dependent patients in a dose of 30-40mg/kg/day.<a href=\"#ref13\" rid=\"ref13\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_511871660\">13</a> Side effects of deferasirox are transient and mild to moderate in intensity. Most common side effects reported are gastrointestinal disturbances (16.6%), increased blood creatinine (11.2%), skin rashes (6.6%) and reversible cytopenias. Elevation of serum liver transaminases is transient and reduced in frequency over time.<a href=\"#ref3\" rid=\"ref3\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_511871651\">3</a>,<a href=\"#ref9\" rid=\"ref9\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_511871650\">9</a> Pediatric growth and adolescent sexual development were not affected.<a href=\"#ref3\" rid=\"ref3\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_511871643\">3</a> As the transfusion and iron chelating therapy is lifelong so there is need to assess the long-term effects of deferasirox.</p><p id=\"__p8\" class=\"p p-last\">Deferasirox is being used in multi-transfused &#x003b2;-thalassemia patients of civil hospital Karachi and previously no study was done to assess the efficacy and side effects of this drug in our setup therefore this study was done to assess the effects of deferasirox in these patients in order to provide better drug monitoring and outcome which can ultimately improve the patients compliance and their quality of life. This study was done to determine the efficacy and adverse effects of oral chelation therapy (Deferasirox) in multi-transfused &#x003b2;-thalassemia major patients visiting pediatric thalassemia clinic in Civil Hospital Karachi.</p></div><div id=\"sec1-2\" class=\"tsec sec\"><h2 class=\"head no_bottom_margin\" id=\"sec1-2title\">METHODS</h2><p id=\"__p9\" class=\"p p-first\">This is a hospital based prospective study conducted at thalassemia clinic of Pediatric Unit-II of Dow University of Health Sciences and Civil Hospital Karachi after approval from the Ethical review board from May 2012 to April 2013 for duration of one year. This is a tertiary care hospital and caters urban and periurban population of Sindh province in Pakistan.</p><p id=\"__p10\">The study included hundred multi-transfused &#x003b2;-thalassemia patients between two to sixteen year of age through convenient sampling. These patients were registered in thalassemia clinic for at least one year and had received optimal oral chelation with deferasirox, 20-40 mg/kg/day for six months or above. Patients with serum ferritin level more than 1000 ng/ml, receiving repeated transfusions were included in the study. Children with multiple transfusions and receiving chelation therapy due to other causes like sickle cell anemia, osteopetrosis, hereditary spherocytosis and auto immune hemolytic anemia were excluded from the study. &#x00392;-thalassemia patients suffering from severe acute illnesses including congestive cardiac failure, renal diseases, bronchopneumonia, hepatitis and deranged liver enzymes at the beginning were also excluded from the study.</p><p id=\"__p11\">All the patients were evaluated through a performa filled by co-investigator and a resident medical officer after informed consent from patient or attendant. These patients were assessed for efficacy and possible adverse effects, nausea, vomiting, abdominal pain, jaundice through history and physical examination. Laboratory investigations including complete blood picture, serum ferritin, creatinine and transaminase levels were done at the initial visit and then repeated after every three months of initiation of deferasirox from Central laboratory of Civil Hospital Karachi.</p><p id=\"__p12\" class=\"p p-last\">Data analyses were done by using SPSS version 16. Mean and Standard Deviation was calculated for quantitative variables like age and laboratory parameters. Qualitative variables like gender, ethnicity, clinical features, nausea, vomiting, jaundice and anemia were presented as frequencies and percentages. The initial laboratory tests were compared after six months by stratification and applying Paired Sample test for quantitative variables.</p></div><div id=\"sec1-3\" class=\"tsec sec\"><h2 class=\"head no_bottom_margin\" id=\"sec1-3title\">RESULTS</h2><p id=\"__p13\" class=\"p p-first\">In this study hundred Thalassemia major children were included. These patients were stratified in to two age groups 54% were below and 46% were above nine year of age. There were 62% males and 38% females. Regarding ethnicity majority were Sindhi, 36%, Pathans 19%, Baloch, 17%, Punjabi, 3% whereas other ethnic groups accounted for 25%.</p><p id=\"__p14\">The frequency of clinical adverse effects shows that anemia was present in 70%, abdominal pain 41%, nausea 31%, vomiting and jaundice was present in 15% patients, respectively. Clinical efficacy was assessed by stratification of serum ferritin, creatinine and serum glutamic pyruvic transaminase (SGPT) values and further evaluated by paired sample test. Serum ferritin values when compared with initial visit and six months after the optimal chelation therapy showed P value of (P=0.929). Haemoglobin P-value was (P=0.892) and serum creatinine (P=0.792) which was statistically non-significant whereas serum SGPT value was statistically significant (P=0.03). Correlation of clinical and laboratory parameters with duration of chelation was also estimated. There was no significant effect of duration of chelation therapy on serum ferritin in patients who received chelation for less than 36 months, 56.9% had value above 2500ng/ml, between 37 to 60 months of chelation therapy 50% and for more than 60 months 100% had value above 2500 ng/ml There was no significant effect of duration of chelation on serum creatinine, it was found abnormal in 11.5% of patients who received chelation for 37-60 months, significant effect of chelation therapy was observed on SGPT values, as the duration of chelation increased the number of patients having abnormal SGPT values were also raised, patients receiving chelation therapy for 60 months or more showed deranged SGPT levels in 100% of cases. Between 37-60 months 57% and below 36 months 70% had abnormal values (<a href=\"/pmc/articles/PMC4485283/table/T1/\" target=\"true\" class=\"fig-table-link table figpopup\" rid-figpopup=\"T1\" rid-ob=\"ob-T1\" co-legend-rid=\"\"><span>Table-I</span></a>).</p><!--table ft1--><!--table-wrap mode=article t1--><div class=\"table-wrap iconblock ten_col whole_rhythm clearfix\" id=\"T1\"><a href=\"/pmc/articles/PMC4485283/table/T1/\" target=\"table\" rid-ob=\"ob-T1\" rid-figpopup=\"T1\" class=\"table img_link icnblk_img figpopup\"><img alt=\"Table-I\" title=\"Table-I\" class=\"small-thumb\" src=\"/pmc/articles/PMC4485283/table/T1/?report=thumb\" src-large=\"/pmc/articles/PMC4485283/table/T1/?report=previmg\" /></a><div class=\"icnblk_cntnt\"><div><a class=\"figpopup\" href=\"/pmc/articles/PMC4485283/table/T1/\" target=\"table\" rid-figpopup=\"T1\" rid-ob=\"ob-T1\">Table-I</a></div><!--caption a4--><div><span>Comparison of laboratory parameters with duration of chelation therapy.</span></div></div></div><p id=\"__p16\" class=\"p\">Comparison of clinical adverse effects with duration of chelation therapy shows that, below 36 months of optimal chelation abdominal pain was 35%, nausea 21%, vomiting 7%, jaundice, 8% anemia was present in 47% patients whereas above 60 months, abdominal pain was 3%, nausea 5% vomiting 3%. Jaundice 2% and anemia, 5% showing that as the duration of chelation increases the severity of adverse effects decreases (<a href=\"/pmc/articles/PMC4485283/table/T2/\" target=\"true\" class=\"fig-table-link table figpopup\" rid-figpopup=\"T2\" rid-ob=\"ob-T2\" co-legend-rid=\"\"><span>Table-II</span></a>). None of the clinical and laboratory adverse effects required withdrawal of treatment.</p><!--table ft1--><!--table-wrap mode=article t1--><div class=\"table-wrap iconblock ten_col whole_rhythm clearfix\" id=\"T2\"><a href=\"/pmc/articles/PMC4485283/table/T2/\" target=\"table\" rid-ob=\"ob-T2\" rid-figpopup=\"T2\" class=\"table img_link icnblk_img figpopup\"><img alt=\"Table-II\" title=\"Table-II\" class=\"small-thumb\" src=\"/pmc/articles/PMC4485283/table/T2/?report=thumb\" src-large=\"/pmc/articles/PMC4485283/table/T2/?report=previmg\" /></a><div class=\"icnblk_cntnt\"><div><a class=\"figpopup\" href=\"/pmc/articles/PMC4485283/table/T2/\" target=\"table\" rid-figpopup=\"T2\" rid-ob=\"ob-T2\">Table-II</a></div><!--caption a4--><div><span>Comparison of clinical adverse effects with duration of chelation therapy.</span></div></div></div></div><div id=\"sec1-4\" class=\"tsec sec\"><h2 class=\"head no_bottom_margin\" id=\"sec1-4title\">DISCUSSION</h2><p id=\"__p18\" class=\"p p-first\">Deferasirox is an effective oral chelator for reducing iron overload in multi-transfused &#x003b2;-thalassemia patients. Iron overload in &#x003b2;-thalassemia major patients is associated with high morbidity and mortality due to complications associated with tissue hemosiderosis. These patients therefore require continuous iron chelation with improve compliance and safety. In recent years multiple iron chelation regimen were used including monotherapy, combined and alternative sequential regimen.<a href=\"#ref14\" rid=\"ref14\" class=\" bibr popnode\">14</a>,<a href=\"#ref15\" rid=\"ref15\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_511871641\">15</a> Deferasirox is used as oral monotherapy due to its prolong half life and selective role in reducing tissue iron of heart and liver, however its efficacy in decreasing high iron overload is unpredictable.<a href=\"#ref16\" rid=\"ref16\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_511871640\">16</a>,<a href=\"#ref17\" rid=\"ref17\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_511871662\">17</a></p><p id=\"__p19\">In the present study also serum ferritin reduced with once oral dose of deferasirox but changes in high values was statistically not significant. On the other hand duration of chelation plays an important role in decline of serum ferritin levels. In earlier studies it was shown that prolong treatment for more than twelve to thirty six months with high doses upto 40mg/kg decreases serum ferritin level significantly,<a href=\"#ref18\" rid=\"ref18\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_511871663\">18</a>,<a href=\"#ref19\" rid=\"ref19\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_511871653\">19</a> in our study there was no significant correlation between duration of chelation and serum ferritin as below thirty six months 56.9% had ferritin levels above 2500ng /ml and 43% less than 2500ng, whereas after sixty months of optimal therapy 41.8% had serum ferritin between 1000-2500ng/ml and 58% showed value above 2500ng/ml, probably due to higher serum ferritin levels at the beginning of chelation or inadequate compliance of the drug. It is also reported that changes in iron burden due to high transfusion requirement and variable gastrointestinal absorption of drug may contribute to variable patient response and require dose adjustments.<a href=\"#ref20\" rid=\"ref20\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_511871659\">20</a></p><p id=\"__p20\">Various studies have documented improved clearance with doses between 30-40 mg/kg/day without any adverse effects. In our study deferasirox was given in maximum dose of 40 mg/kg/daywith high serum ferritin levels and in patients who did not responded to low dose but there was no increased incidence of adverse effects. Deferasirox is although well tolerated with high safety profile but most common adverse effcts reported are gastrointestinal disturbances, increase liver enzymes, maculopapular skin rash and elevation of serum creatinine levels. In the present study most frequently observed side effects of deferasirox were gastrointestinal symptoms including abdominal pain 41%, nausea 31%, jaundice was found in 15% respectively. Other recent studies has also shown comparable results.<a href=\"#ref21\" rid=\"ref21\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_511871649\">21</a>,<a href=\"#ref22\" rid=\"ref22\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_511871657\">22</a></p><p id=\"__p21\">Another significant adverse effect documented in the present study was elevated liver enzymes, 69% showed raised SGPT after six months of therapy. Duration of therapy also has significant effect on serum SGPT levels, in the present study number of patients having elevated liver enzymes rises with prolong duration of therapy, below thirty six months 70% had raised SGPT levels whereas above sixty months of chelation all patients showed elevated liver enzymes, other studies also reported raised hepatic enzymes levels with increased duration of therapy.<a href=\"#ref13\" rid=\"ref13\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_511871646\">13</a> Serum creatinine in various studies was reported to be elevated with prolomg duration of deferasirox therapy,<a href=\"#ref23\" rid=\"ref23\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_511871637\">23</a> however in this study it was raised only in 11.5% patients after thirty six months of chelation. Another significant finding in our study was improvement in gastrointestinal symptoms after thirty six months which is not reported previously however one of the earlier studies has shown improvement in liver enzymes at twenty four to thirty six months of treatment.<a href=\"#ref24\" rid=\"ref24\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_511871645\">24</a></p><p id=\"__p22\" class=\"p\">Most of the adverse effects reported in the present study were mild and did not require dose adjustment or cessation of therapy except in few patients with elevated liver enzymes, temporary withdrawal of chelation dropped enzymes levels to normal values, other clinical trials have also reported dose adjustment and interruption of therapy in few patients only.<a href=\"#ref25\" rid=\"ref25\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_511871664\">25</a></p><div id=\"sec2-1\" class=\"sec sec-last\"><h3>Limitation of the study</h3><p id=\"__p23\" class=\"p p-first-last\">Limitation of the present study were less number of patients, loss for follow-ups and few patients previously on combined therapy of oral deferasirox and parenteral desferral for prolong period who were switched to monotherapy of oral deferasirox probably resulting in data bias, however oral deferasirox showed a better safety profile with good compliance and ability to provide prolong chelation therapy with minimal adverse effects.</p></div></div><div id=\"sec1-5\" class=\"tsec sec\"><h2 class=\"head no_bottom_margin\" id=\"sec1-5title\">CONCLUSION</h2><p id=\"__p24\" class=\"p p-first-last\">Deferasirox is an effective oral chelation agent for &#x003b2;-thalassemia major patients with few adverse effects. The study results shows that deferasirox reduces serum ferritin levels after long term therapy, however changes in serum ferritin values were statistically not significant. Most common adverse effects of the drug were gastrointestinal symptoms including abdominal pain, nausea, vomiting and elevation of liver enzymes. Patients receiving deferasirox should be monitored regularly for timely management of side effects that may occur with long term treatment in order to improve compliance and efficacy.</p></div><div id=\"__ackid1448606\" class=\"tsec sec\"><h2 class=\"head no_bottom_margin\" id=\"__ackid1448606title\">ACKNOWLEDGEMENT</h2><div class=\"sec\"><p id=\"__p25\">Authors are thankful to the staff of department of pediatrics for their support and Mr. Muhammad Furqan Baig for secretarial assistance in conducting the study.</p></div></div><div id=\"sec2-2\" class=\"tsec bk-sec\"><h2 class=\"head no_bottom_margin\" id=\"sec2-2title\">Authors&#x02019; Contribution</h2><!--/article/back/sec/--><p id=\"__p26\" class=\"p p-first\"><strong><em>Dr. Muzamil Shabana Ejaz:</em></strong> Conception, designing, data analysis, interpretation, manuscript writing, editing and review.</p><p id=\"__p27\"><strong><em>Dr. Shagufta Baloch:</em></strong> Data collection, analysis and compiling of results, manuscript writing.</p><p id=\"__p28\" class=\"p p-last\"><strong><em>Prof. Fehmina Arif:</em></strong> Reviewing, editing and final approval of manuscript.</p></div><div id=\"__ref-listid1446646\" class=\"tsec sec\"><h2 class=\"head no_bottom_margin\" id=\"__ref-listid1446646title\">REFERENCES</h2><div class=\"ref-list-sec sec\" id=\"reference-list\"><div class=\"ref-cit-blk half_rhythm\" id=\"ref1\">1. <span class=\"element-citation\">Shamsi TS. &#x003b2;-thalassemia- a major health problem in Pakistan. <span><span class=\"ref-journal\">J Pak Med Assoc. </span>2004;<span class=\"ref-vol\">54</span>:10.</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/15552280\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4485283&amp;issue-id=254739&amp;journal-id=2162&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref2\">2. <span class=\"element-citation\">Shamsshiraz AA, Bekheimia MR, Kamgar M, Pourehedgilani N, Bouzari N, Habibzadeh M, et al.  Metabolic and endocrinologic complications in beta-thalassemia major: a multicenter study in Tehran. <span><span class=\"ref-journal\">BMC Endocrine Disorders. </span>2003;<span class=\"ref-vol\">3</span>:23\u201334.</span> <span class=\"nowrap ref pmc\">[<a class=\"int-reflink\" href=\"/pmc/articles/PMC194672/\">PMC free article</a>]</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/12914670\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4485283&amp;issue-id=254739&amp;journal-id=2162&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref3\">3. <span class=\"element-citation\">Cappellini MD, Bejaoui M, Agaoglu L, et al.  Iron chelation with deferasirox in adults and pediatric patients with Thalassemia major: efficacy and safety during 5 years&#x02019; follow&#x02013;up. <span><span class=\"ref-journal\">Blood. </span>2011;<span class=\"ref-vol\">118</span>(4):884\u2013893.</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/21628399\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4485283&amp;issue-id=254739&amp;journal-id=2162&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref4\">4. <span class=\"element-citation\">Low LC. Growth of children with &#x003b2;-thalassemia major. <span><span class=\"ref-journal\">Indian J Pediatr. </span>2005;<span class=\"ref-vol\">72</span>(2):159\u2013164.</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/15758540\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4485283&amp;issue-id=254739&amp;journal-id=2162&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref5\">5. <span class=\"element-citation\">Taher A, El-Beshlawy A, Elalfy MS, AlZir K, Daar S, Habr D, et al.  Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassemia: the ESCALATOR study. <span><span class=\"ref-journal\">E J Haematol. </span>2009;<span class=\"ref-vol\">82</span>(6):458\u2013465.</span> <span class=\"nowrap ref pmc\">[<a class=\"int-reflink\" href=\"/pmc/articles/PMC2730551/\">PMC free article</a>]</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/19187278\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4485283&amp;issue-id=254739&amp;journal-id=2162&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref6\">6. <span class=\"element-citation\">Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A, et al.  Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparision to deferoxamine in thalassemia patients with transfusional iron overload. <span><span class=\"ref-journal\">Haematologica. </span>2006;<span class=\"ref-vol\">91</span>(7):873\u2013880.</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/16818273\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4485283&amp;issue-id=254739&amp;journal-id=2162&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref7\">7. <span class=\"element-citation\">Hoffbrand A, Cohen A, Hershko C. Role of Deferiprone in chelation therapy for transfusional iron over load. <span><span class=\"ref-journal\">Blood. </span>2003;<span class=\"ref-vol\">102</span>:17\u201324.</span> doi: 10.1182/blood-2002-06-1867.  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/12637334\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4485283&amp;issue-id=254739&amp;journal-id=2162&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref8\">8. <span class=\"element-citation\">Meerpohl JJ, Antes G, R&#x000fc;cker G, Fleeman N, Motschall E, Niemeyer CM, et al.  Deferasirox for managing iron overload in people with Thalassemia. <span><span class=\"ref-journal\">Cochrane Database Sys Rev. </span>2012 Feb 15;<span class=\"ref-vol\">2</span>:CD007476.</span> doi: 10.1002/14651858.CD007476.pub2.  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/22336831\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4485283&amp;issue-id=254739&amp;journal-id=2162&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref9\">9. <span class=\"element-citation\">Panigrahi I, Vaidya PC, Bansal D, Marwaha RK. Efficacy of Deferasirox in North Indian &#x003b2;-thalassemia major patient a preliminary report. <span><span class=\"ref-journal\">J Pediatr Hematol Oncol. </span>2012;<span class=\"ref-vol\">34</span>(1):51\u201353.</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/22215098\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4485283&amp;issue-id=254739&amp;journal-id=2162&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref10\">10. <span class=\"element-citation\">Agarwal MB. Deferasirox. Oral, Once Daily Iron Chelator- An Expert Opinion. <span><span class=\"ref-journal\">Indian J Pediatr. </span>2010;<span class=\"ref-vol\">77</span>(2):185\u2013191.</span> doi: 10.1007/s12098-010-0030-4.  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/20178010\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4485283&amp;issue-id=254739&amp;journal-id=2162&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref11\">11. <span class=\"element-citation\">Gao HY, Li Q, Chen JJ, Chen GF, Li CG. Curative effects and safety of deferasirox in treatment of iron overloaded in children with &#x003b2;-thalassemia major. <span><span class=\"ref-journal\">Zhongguo Dang Dai Er Ke Za Zhi. </span>2011;<span class=\"ref-vol\">13</span>(7):531\u2013534.</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/21752315\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4485283&amp;issue-id=254739&amp;journal-id=2162&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref12\">12. <span class=\"element-citation\">Cappellin MD, Taher A. Deferasirox (Exjade) for the treatment of iron overload. <span><span class=\"ref-journal\">Acta Haematol. </span>2009;<span class=\"ref-vol\">122</span>(2-3):165\u2013173.</span> doi: 10.1159/000243801.  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/19907154\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4485283&amp;issue-id=254739&amp;journal-id=2162&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref13\">13. <span class=\"element-citation\">Chaudhary P, Pullashat V. Deferasirox;Appraisel of Saftey and Efficacy in Long Term Therapy. J Blood Med. <span><span class=\"ref-journal\">Blood Med. </span>2013;<span class=\"ref-vol\">4</span>:101\u201310.</span> doi: 10.2147/JBM.S35478. <span class=\"nowrap ref pmc\">[<a class=\"int-reflink\" href=\"/pmc/articles/PMC3743529/\">PMC free article</a>]</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/23966805\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4485283&amp;issue-id=254739&amp;journal-id=2162&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref14\">14. <span class=\"element-citation\">Keikaci B. Sequential Deferoxamine &#x02013; Defrasirox in Treatment of Major Thalassemia with Iron Overload. <span><span class=\"ref-journal\">Iraninan J Paediatr Hematol Oncol. </span>2010:14\u201319.</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref15\">15. <span class=\"element-citation\">Cabantchik ZL, Breuer W, Zaminelli Gci, Aneiulli P. Lpi-Labile Plasma Iron in Iron-Overload. <span><span class=\"ref-journal\">Best Pract Res Clin Haematol. </span>2005;<span class=\"ref-vol\">182</span>:277\u2013287.</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/15737890\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4485283&amp;issue-id=254739&amp;journal-id=2162&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref16\">16. <span class=\"element-citation\">Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Neufeld EJ, S&#x000e9;chaud R, et al.  Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. <span><span class=\"ref-journal\">Lancet. </span>2003;<span class=\"ref-vol\">361</span>(9369):1597\u20131602.</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/12747879\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4485283&amp;issue-id=254739&amp;journal-id=2162&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref17\">17. <span class=\"element-citation\">Nick H, Anklin P, Lattmann R, Buehlmayer P, Hauffe S, Schupp J, et al.  Development of Tri Dentate Iron Chelaton: From Desferrrithiocin To Icl 670. <span><span class=\"ref-journal\">Curr Med Chem. </span>2003;<span class=\"ref-vol\">10</span>(12):1065\u20131076.</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/12678677\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4485283&amp;issue-id=254739&amp;journal-id=2162&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref18\">18. <span class=\"element-citation\">Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, et al.  A Phase I Study Of Deferasirox (Icl670), A Once Daily Oral Iron Chelator, In Patients With Beta Thalassemia. <span><span class=\"ref-journal\">Blood. </span>2006;<span class=\"ref-vol\">107</span>(9):3455\u20133462.</span> doi: 10.1182/blood-2005-08-3430.  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/16352812\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4485283&amp;issue-id=254739&amp;journal-id=2162&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref19\">19. <span class=\"element-citation\">Tahir A, Cappelline MD, Vichins BE. Efficacy And Safety Of Deferasiox Doses Of 30 mg/kg/day, In Patients With Transfusion Dependent Anemia and Iron Overload. <span><span class=\"ref-journal\">Br J Haematol. </span>2009;<span class=\"ref-vol\">147</span>:752\u2013759.</span> <span class=\"nowrap ref pmc\">[<a class=\"int-reflink\" href=\"/pmc/articles/PMC2779992/\">PMC free article</a>]</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/19764988\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4485283&amp;issue-id=254739&amp;journal-id=2162&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref20\">20. <span class=\"element-citation\">Chirmoman D, Smith A, Braunstein J, Finkelstein Y, Pereira L, Bergmann AK, et al.  Defersiarox Pharmacokineticks in patients with adequate versus inadequate response. <span><span class=\"ref-journal\">Blood. </span>2009;<span class=\"ref-vol\">114</span>(19):4009\u20134013.</span> <span class=\"nowrap ref pmc\">[<a class=\"int-reflink\" href=\"/pmc/articles/PMC2774541/\">PMC free article</a>]</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/19724055\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4485283&amp;issue-id=254739&amp;journal-id=2162&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref21\">21. <span class=\"element-citation\">Chandra J, Chaudary H, Pemde H, Singh V, Dutta AK. Safety and efficacy of Deferasiarox in multitransfused Indian children with B-thalassemia major. <span><span class=\"ref-journal\">Ann Trop Paediatr. </span>2011;<span class=\"ref-vol\">31</span>(1):47\u201351.</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/21262109\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4485283&amp;issue-id=254739&amp;journal-id=2162&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref22\">22. <span class=\"element-citation\">Aycicek A, Koc A, Abuhandan M. Efficacy of deferasirox in children with &#x003b2;-thalassemia: Single-center 3 year experience. <span><span class=\"ref-journal\">Pediatr Int. </span>2014;<span class=\"ref-vol\">56</span>(4):530\u2013533.</span> doi: 10.1111/ped.12323.  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/24612039\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4485283&amp;issue-id=254739&amp;journal-id=2162&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref23\">23. <span class=\"element-citation\">Dhamija M, Mahajan A, Kalra M, Virman A. Deferasirox in Indian children with thalassemia major: 3 years experience. <span><span class=\"ref-journal\">Indian J Med Paediatr Onclo. </span>2013;<span class=\"ref-vol\">34</span>(1):16\u201320.</span> doi: 10.4103/0971-5851.113407. <span class=\"nowrap ref pmc\">[<a class=\"int-reflink\" href=\"/pmc/articles/PMC3715972/\">PMC free article</a>]</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/23878481\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4485283&amp;issue-id=254739&amp;journal-id=2162&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref24\">24. <span class=\"element-citation\">Merchant R, Ajmed J, Krishanan P, Jankaria B. Efficacy and safety of Deferasirox for reducing total body and cardiac iron in Thalassemia. <span><span class=\"ref-journal\">Indian Pediatr. </span>2012;<span class=\"ref-vol\">49</span>(4):281\u2013285.</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/21992861\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4485283&amp;issue-id=254739&amp;journal-id=2162&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"ref25\">25. <span class=\"element-citation\">Al-Khabori M, Bhandari S, Al-Huneni M, Al-Farsi K, Panjwani V, Daar S. Side effects of Deferasirox Iron Chelation in Patients with Beta Thalassemia Major or Intermedia. <span><span class=\"ref-journal\">Oman Med J. </span>2013;<span class=\"ref-vol\">28</span>(2):121\u2013124.</span> doi: 10.5001/omj.2013.31. <span class=\"nowrap ref pmc\">[<a class=\"int-reflink\" href=\"/pmc/articles/PMC3628199/\">PMC free article</a>]</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/23599881\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4485283&amp;issue-id=254739&amp;journal-id=2162&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div></div></div></div><!--post-content--><hr class=\"whole_rhythm no_bottom_margin\" /><div class=\"courtesy-note no_margin small\">Articles from <span class=\"acknowledgment-journal-title\">Pakistan Journal of Medical Sciences</span> are provided here courtesy of <strong>Professional Medical Publications</strong></div></div>\n            \n            \n        \n            \n        </div>\n        <!-- Book content -->\n    </div>\n    \n    <div id=\"rightcolumn\" class=\"four_col col last\">\n        <!-- Custom content above discovery portlets -->\n        <div class=\"col6\">\n            \n        </div>\n        \n        <div xmlns:np=\"http://ncbi.gov/portal/XSLT/namespace\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\"><div class=\"format-menu\"><h2>Formats:</h2><ul><li class=\"selected\">Article</li> | <li><a href=\"/pmc/articles/PMC4485283/?report=reader\">PubReader</a></li> | <li class=\"epub-link\"><a href=\"/pmc/articles/PMC4485283/epub/\">ePub (beta)</a></li> | <li><a href=\"/pmc/articles/PMC4485283/pdf/PJMS-31-621.pdf\">PDF (756K)</a></li> | <li><a href=\"#\" data-citationid=\"PMC4485283\" class=\"citationexporter ctxp\">Citation</a></li></ul></div></div><div xmlns:np=\"http://ncbi.gov/portal/XSLT/namespace\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\" class=\"share-buttons\"><h2>Share</h2><ul><li class=\"facebook\"><a href=\"https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4485283%2F\"><img src=\"//static.pubmed.gov/portal/portal3rc.fcgi/4132802/img/4047626\" alt=\"Share on Facebook\" />\n                             Facebook\n                        </a></li><li class=\"twitter\"><a href=\"https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4485283%2F&amp;text=Efficacy%20and%20adverse%20effects%20of%20oral%20chelating%20therapy%20(deferasirox)%20in%20multi-transfused%20Pakistani%20children%20with%20%CE%B2-thalassemia%20major\"><img src=\"//static.pubmed.gov/portal/portal3rc.fcgi/4132802/img/4047627\" alt=\"Share on Twitter\" />\n                             Twitter\n                        </a></li><li class=\"gplus\"><a href=\"https://plus.google.com/share?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4485283%2F\"><img src=\"//static.pubmed.gov/portal/portal3rc.fcgi/4132802/img/4047628\" alt=\"Share on Google Plus\" />\n                             Google+\n                        </a></li></ul></div>\n        \n        <div id=\"ajax-portlets\" data-pmid=\"26150856\" data-aiid=\"4485283\" data-aid=\"4485283\" data-iid=\"254739\" data-domainid=\"2162\" data-domain=\"pakjmedsci\" data-accid=\"PMC4485283\" data-md5=\"cf11cec411d696e9da2de020ad33b1af\"></div>\n                \n        <!-- Custom content below discovery portlets -->\n        <div class=\"col7\">\n            \n        </div>\n    </div>\n</div>\n\n<!-- Custom content after all -->\n<div class=\"col8\">\n    \n</div>\n<div class=\"col9\">\n    \n</div>\n\n<script src=\"/corehtml/pmc/js/jquery.scrollTo-1.4.2.js\"></script>\n<script>\n    (function($){\n        $('.skiplink').each(function(i, item){\n            var href = $($(item).attr('href'));\n            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus\n            $(item).on('click', function(event){\n                event.preventDefault();\n                $.scrollTo(href, 0, {\n                    onAfter: function(){\n                        href.focus();\n                    }\n                });\n            });\n        });\n    })(jQuery);\n</script>\n\n\n\n<div id=\"body-link-poppers\"></div>\n                        </div>\n                        <div class=\"bottom\">\n                            \n                            <div id=\"NCBIFooter_dynamic\">\n    <div class=\"breadcrumbs\">You are here: \n            <span id=\"breadcrumb_text\"><a href=\"/guide/\">NCBI</a> &gt; <a href=\"https://www.ncbi.nlm.nih.gov/guide/literature/\">Literature</a> &gt; <a href=\"https://www.ncbi.nlm.nih.gov/pmc/\">PubMed Central (PMC)</a></span></div>\n    <a id=\"help-desk-link\" class=\"help_desk jig-ncbihelpwindow\" target=\"_blank\" href=\"/sites/ehelp?&amp;Ncbi_App=pmc&amp;Db=pmc&amp;Page=literature&amp;Snapshot=/projects/PMC/PMCViewer@4.39&amp;Time=2016-11-05T22:45:25-04:00&amp;Host=ptpmc202\">Write to the Help Desk</a>\n    \n</div>\n\n                            <div class=\"footer\" id=\"footer\">\n    \n    <div class=\"subfooter\"> </div><script type=\"text/javascript\" src=\"/portal/portal3rc.fcgi/static/js/preloaderWidget.js\"> </script>\n    <div id=\"external-disclaimer\" class=\"offscreen_noflow\">\n        External link. Please review our <a href=\"https://www.nlm.nih.gov/privacy.html\">privacy policy</a>.\n    </div>    \n    <div id=\"ncbifooter\" class=\"contact_info\">      \n        <div id=\"footer-contents-right\">\n            <div id=\"nlm_thumb_logo\">\n                <a href=\"https://www.nlm.nih.gov\" title=\"NLM\">NLM</a>\n            </div>\n            <div id=\"nih_thumb_logo\">\n                <a href=\"https://www.nih.gov\" title=\"NIH\">NIH</a>\n            </div>\n            <div id=\"hhs_thumb_logo\">\n                <a href=\"https://www.hhs.gov\" title=\"DHHS\">DHHS</a>\n            </div>\n            <div id=\"usagov_thumb_logo\">\n                <a href=\"https://www.usa.gov\" title=\"USA.gov\">USA.gov</a>\n            </div>         \n        </div>\n        \n        <div id=\"footer-contents-left\">\n            <p class=\"address vcard\">\n                <span class=\"url\">\n                    <a class=\"fn url newdomain\" href=\"https://www.ncbi.nlm.nih.gov\">National Center for\n                        Biotechnology Information</a>,\n                </span> <span class=\"org url newdomain\"><a href=\"https://www.nlm.nih.gov/\">U.S. National Library of Medicine</a></span>\n                <span class=\"adr\">\n                    <span class=\"street-address\">8600 Rockville Pike</span>, <span class=\"locality\">Bethesda</span>\n                    <span class=\"region\">MD</span>, <span class=\"postal-code\">20894</span>\n                    <span class=\"country-name\">USA</span>\n                </span>\n            </p>\n            \n            <a href=\"/home/about/policies.shtml\">Policies and Guidelines</a> | <a href=\"/home/about/contact.shtml\">Contact</a>\n        </div>\n    </div>\n    <script type=\"text/javascript\" src=\"/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1\"> </script>    \n    <script type=\"text/javascript\" src=\"/portal/portal3rc.fcgi/static/js/hfjs2.js\"> </script>\n</div>\n                        </div>\n                    </div>\n                    <!--/.page-->\n                </div>\n                <!--/.wrap-->\n            </div><!-- /.twelve_col -->\n        </div>\n        <!-- /.grid -->\n\n        <span class=\"PAFAppResources\"></span>\n        \n        <!-- BESelector tab -->\n        \n        \n        \n        <noscript><img alt=\"statistics\" src=\"/stat?jsdisabled=true&amp;ncbi_db=pmc&amp;ncbi_pdid=article&amp;ncbi_acc=&amp;ncbi_domain=pakjmedsci&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/articles/PMC4485283/&amp;ncbi_app=pmc\" /></noscript>\n        \n        \n        <!-- usually for JS scripts at page bottom -->\n        <!--<component id=\"PageFixtures\" label=\"styles\"></component>-->\n    \n\n<!-- F4FC524A81E99451_0119SID /projects/PMC/PMCViewer@4.39 ptpmc202 v4.1.r508797 Mon, Aug 01 2016 12:51:16 -->\n\n<script type=\"text/javascript\" src=\"//static.pubmed.gov/portal/portal3rc.fcgi/4132802/js/3879255/4121861/3818874/3821238/4117325/4087685/4072593/4076480/3921943/4105668/4065628.js\" snapshot=\"pmc\"></script></body>\n</html>"}